Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

C. Male, A.W.A. Lensing, J.S. Palumbo, R. Kumar, I. Nurmeev, K. Hege, D. Bonnet, P. Connor, H.L. Hooimeijer, M. Torres, A.K.C. Chan, G. Kenet, S. Holzhauer, A. Santamaria, P. Amedro, E. Chalmers, P. Simioni, R.V. Bhat, D.L. Yee, O. LvovaJ. Beyer-Westendorf, T.T. Biss, I. Martinelli, P. Saracco, M. Peters, K. Kallay, C.A. Gauger, M.P. Massicotte, G. Young, A.F. Pap, M. Majumder, W.T. Smith, J.F. Heubach, S.D. Berkowitz, K. Thelen, D. Kubitza, M. Crowther, M.H. Prins, P. Monagle, EINSTEIN-Jr Phase 3 Investigators

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E18-E27
Number of pages10
JournalThe Lancet Haematology
Volume7
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • definition
  • disease
  • oral rivaroxaban
  • thrombosis
  • DEFINITION
  • ORAL RIVAROXABAN
  • THROMBOSIS
  • DISEASE

Cite this